Posts

Posted on

World Wide Farms Partners with ReposiTrak to Strengthen Food Safety and Supply Chain Transparency with End-to-End Traceability

World Wide Farms Partners with ReposiTrak to Strengthen Food Safety and Supply Chain Transparency with End-to-End Traceability

Leading Purveyor of Fresh Herbs and Greens Chooses the World’s Largest Traceability Network to Collect and Share Accurate Food Data

CHICAGO & SALT LAKE CITY–(BUSINESS WIRE)–
World Wide Farms, a leading grower, packer, and distributor of fresh culinary herbs and greens, has announced its use of the ReposiTrak Traceability Network® for inbound and outbound traceability data sharing. This collaboration amplifies World Wide Farms’ commitment to food safety, regulatory compliance, and supply chain transparency by leveraging ReposiTrak’s advanced traceability solution for the exchange of accurate traceability data.​

Founded in 1986 and headquartered in Wauconda, Ill., World Wide Farms has remained dedicated to sustainable farming practices and the delivery of high-quality produce. With operations throughout the United States and Mexico, the company supplies major retailers and food service providers across the Midwest. By adopting the ReposiTrak Traceability Network, World Wide Farms is enhancing its ability to collect and share traceability data in compliance with the FDA’s Food Safety Modernization Act (FSMA) 204, set to take effect in 2028.

“At World Wide Farms, our commitment has always been to delivering safe, fresh, and sustainably grown herbs and greens,” said Daniel Lyons, President of World Wide Farms. “To uphold that promise, we needed a highly accurate traceability solution for both inbound and outbound shipments. Partnering with ReposiTrak not only positions us well for upcoming regulatory changes – it also enhances our supply chain transparency and boosts operational efficiency.”

Every data file received by ReposiTrak is put through a comprehensive500+ point error detection process to ensure accuracy and consistency. When errors are identified, notifications are sent and ReposiTrak’s U.S.-based team works directly with suppliers to make the necessary corrections. This hands-on approach ensures that the data is as accurate as possible before it’s shared with World Wide Farms’ customers.

“We are thrilled to welcome World Wide Farms to our growing traceability network,” said Randy Fields, chairman and CEO of ReposiTrak. “Traceability is a food safety issue that requires a supply chain solution – especially for companies like theirs that are responsible for inbound data from growers and outbound data for customers. Every date file we receive is put through a rigorous set of controls to ensure accuracy BEFORE the data gets stored and/or passed along. It’s something that sets us apart and that we’re proud to share with World Wide Farms.”

By adopting ReposiTrak’s traceability solutions, World Wide Farms is taking a proactive step toward a more resilient and trustworthy food supply chain.​

About World Wide Farms

Founded in 1986 and part of Hoffmann Family of Companies, World Wide Farms is a premier grower, packer, and distributor of fresh culinary herbs and greens. With farming operations in the United States and Mexico, the company is committed to sustainable agriculture and delivering high-quality produce to retailers and food service providers across the Midwest. For more information, visit worldwidefarms.net.​

About ReposiTrak

ReposiTrak (NYSE: TRAK) provides retailers, suppliers and wholesalers with a robust solution suite consisting of three product families: food traceability, compliance and risk management and supply chain solutions. ReposiTrak’s integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit repositrak.com.

Rachel Berkowitz

World Wide Farms

[email protected]

Derek Hannum

Chief Customer Officer

ReposiTrak

[email protected]

KEYWORDS: United States North America Utah Illinois

INDUSTRY KEYWORDS: Data Management Supply Chain Management Technology Supermarket Food/Beverage Agriculture Natural Resources Apps/Applications Retail Software Networks

MEDIA:

Logo
Logo
Posted on

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Individuals can access the conference call by dialing:

US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297

Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:

David Holmes
[email protected]



Posted on

Inyo Mobility Selects Aeva 4D LiDAR to Power Next-Generation Autonomous Shuttle Fleet

Inyo Mobility Selects Aeva 4D LiDAR to Power Next-Generation Autonomous Shuttle Fleet

Multiple Aeva Atlas 4D LiDAR Sensors to Provide 360-degrees of Sensing for L4 Full Autonomy

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Aeva® (Nasdaq: AEVA), a leader in next-generation sensing and perception systems, today announced that Inyo Mobility, a leader in autonomous urban transportation solutions, has selected Aeva as the exclusive LiDAR supplier for its upcoming autonomous shuttle program. The partnership will integrate Aeva’s cutting-edge Aeva Atlas™ 4D LiDAR technology into Inyo’s autonomous vehicle platform, aiming to enhance safety, perception, and operational efficiency in complex urban environments.​

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422548401/en/

Inyo Mobility's next-generation autonomous Inyo CAB equipped with Aeva Atlas 4D LiDAR sensors.

Inyo Mobility’s next-generation autonomous Inyo CAB equipped with Aeva Atlas 4D LiDAR sensors.

Inyo is pioneering the use of compact, lightweight vehicles in public transport, focusing on resource and cost-efficient, customizable designs tailored to specific applications throughout Europe. The Inyo CAB is a fully electric modular vehicle designed for sustainable, last-mile urban mobility, featuring a customizable interior, barrier-free access, and multiple autonomous and manually operated configurations for both passenger and cargo transport.

The collaboration between Inyo Mobility and Aeva represents a significant step forward in the deployment of autonomous vehicles for public transportation. By leveraging Aeva’s high-performance LiDAR technology, Inyo aims to enhance the safety and reliability of its shuttle services, providing cities with a dependable and efficient transportation option.​

Aeva’s 4D LiDAR, based on Frequency Modulated Continuous Wave (FMCW) technology, uniquely provides simultaneous measurement of 3D position and instant velocity for each point in a scene. This capability allows autonomous vehicles to better distinguish between static and dynamic objects, such as pedestrians, cyclists, and other vehicles, even at long ranges and in challenging weather conditions. Aeva’s sensors can detect objects up to 500 meters away and are immune to interference from other LiDAR sensors and sunlight, making them particularly suited for urban and highway driving scenarios.​

“We are excited to partner with Aeva to equip our vehicle fleet with their state-of-the-art 4D LiDAR technology,” said Marcus Zwick, CEO of Inyo Mobility. “Aeva’s compact sensors will integrate seamlessly and provide our vehicles with a comprehensive 360-degree understanding of their surroundings, enabling safer and more reliable autonomous operation in the dynamic environments of city streets.”​

“Inyo Mobility’s commitment to deploying advanced autonomous transportation aligns perfectly with our mission to bring next-generation perception solutions to the mobility industry,” said James Byun, Managing Director of Business Development at Aeva. “We look forward to supporting Inyo’s autonomous shuttle program and contribute to the advancement of safe and efficient urban mobility.”​

About Inyo Mobility

Inyo Mobility is a pioneering autonomous vehicle company dedicated to transforming urban transportation through innovative technology. With a focus on safety, efficiency, and sustainability, Inyo develops and deploys autonomous mobility solutions designed to meet the evolving needs of modern cities.​

About Aeva Technologies, Inc. (Nasdaq: AEVA)

Aeva’s mission is to bring the next wave of perception to a broad range of applications from automated driving to industrial robotics, consumer electronics, consumer health, security and beyond. Aeva is transforming autonomy with its groundbreaking sensing and perception technology that integrates all key LiDAR components onto a silicon photonics chip in a compact module. Aeva 4D LiDAR sensors uniquely detect instant velocity in addition to 3D position, allowing autonomous devices like vehicles and robots to make more intelligent and safe decisions. For more information, visit www.aeva.com, or connect with us on X or LinkedIn.

Aeva, the Aeva logo, Aeva 4D LiDAR, Aeva Atlas, Aeries, Aeva Ultra Resolution, Aeva CoreVision, and Aeva X1 are trademarks/registered trademarks of Aeva, Inc. All rights reserved. Third-party trademarks are the property of their respective owners.

Forward-looking statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements include, but are not limited to expectations about our product features, performance and our relationship with Inyo Mobility. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to: (i) the fact that Aeva is an early stage company with a history of operating losses and may never achieve profitability, (ii) Aeva’s limited operating history, (iii) the ability to implement business plans, forecasts, and other expectations and to identify and realize additional opportunities, (iv) the ability to manufacture at volumes and costs needed for commercial programs, (vi) that any programs into which our products may be designed will result in significant end customer sales, (vii) unforeseen project delays or product issues, such as difficulties or delays in shipping, manufacturing or installation, and (viii) other material risks and other important factors that could affect our financial results. Please refer to our filings with the SEC, including our most recent Form 10-Q and Form 10-K. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Aeva assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Aeva does not give any assurance that it will achieve its expectations.

Media:

Michael Oldenburg

[email protected]

Investors:

Andrew Fung

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Public Transport Mobile/Wireless Technology Automotive Transport Automotive Manufacturing Manufacturing Hardware Autonomous Driving/Vehicles Logistics/Supply Chain Management

MEDIA:

Photo
Photo
Inyo Mobility’s next-generation autonomous Inyo CAB equipped with Aeva Atlas 4D LiDAR sensors.
Logo
Logo
Posted on

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

  • Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk
  • BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension who are the focus of the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT)
  • BDD status provides accelerated FDA engagement and reviews for AVIM therapy; it also supports potential pathways to secure higher reimbursement for AVIM-enabled devices in the future

NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy.

Specifically, the BDD is for an implantable system (i.e., a pacemaker) to deliver AVIM therapy using conduction system pacing to reduce blood pressure in patients with increased ten-year atherosclerotic cardiovascular disease (“ASCVD”) risk, preserved left ventricular systolic function, and uncontrolled hypertension, despite the use of anti-hypertensive medications or in patients who may have intolerance to anti-hypertensive medications. Orchestra BioMed estimates that there are over 7.7 million patients in the U.S. that meet the criteria for the BDD for AVIM therapy. AVIM therapy is currently being evaluated under an FDA investigational device exemption (“IDE”) in the BACKBEAT global pivotal study which is being conducted by Orchestra BioMed in collaboration with Medtronic. The BACKBEAT pivotal study is enrolling pacemaker-indicated patients with uncontrolled hypertension despite the use of anti-hypertensive medication, a key subpopulation under the BDD for which Orchestra BioMed believes AVIM therapy may offer optimal clinical benefit.

“We are delighted to have received FDA Breakthrough Device Designation for AVIM therapy which has the potential to offer a differentiated, advantageous solution for hypertension management in a broad population,” commented David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed. “Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in collaboration with Medtronic. The FDA Breakthrough Device Designation recognizes the potential of this unique therapy to benefit a significantly expanded number of patients who are not indicated for a pacemaker but who also have uncontrolled hypertension and increased cardiovascular risk. We are committed to working closely with the FDA, Medtronic and the clinical community to maximize the impact of AVIM therapy.”

The FDA Breakthrough Devices Program, which reflects the FDA’s commitment to device innovation and protecting public health, is designed to expedite the development and provide priority review of innovative medical technologies that have the potential to significantly improve outcomes for patients with serious or life-threatening conditions. To be eligible for this designation, a device must demonstrate the potential to provide more effective treatment or diagnosis of a life-threatening or irreversibly debilitating condition. In addition, the device must meet at least one of the following criteria: it must represent breakthrough technology, have no approved or cleared alternatives, offer significant advantages over existing options, or be determined by the FDA to be in the best interest of patients.

Beyond regulatory acceleration, the Breakthrough designation may also support favorable reimbursement pathways, including eligibility for incremental inpatient reimbursement through the New Technology Add-on Payment (“NTAP”) and outpatient Transitional Pass-Through payments (“TPT”) under the Center for Medicare & Medicaid Services (“CMS”) programs. These mechanisms may help facilitate more timely access to breakthrough technologies while supporting provider adoption and patient access.

“We are very pleased that AVIM therapy received Breakthrough Device Designation, a recognition of the potential of AVIM therapy to address unmet needs in hypertension management,” said Robert C. Kowal, M.D., Ph.D., Vice President and General Manager of Cardiac Pacing Therapies within the Medtronic Cardiac Rhythm Management operating unit. “Hypertension remains a significant global public health challenge that is especially relevant to the pacemaker population as the most common comorbidity in these patients. Medtronic is committed to collaborating with Orchestra BioMed to advance this innovative, investigational therapy through the BACKBEAT global pivotal study.”

Orchestra BioMed has a strategic collaboration with Medtronic, the global market leader in cardiac pacing therapies, for development and commercialization of AVIM therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. Under the terms of the existing collaboration agreement, Medtronic holds the right of first negotiation to expand its licensing agreement with Orchestra BioMed to obtain global rights to commercialize AVIM therapy for the treatment of uncontrolled hypertension in patients that do not have an indication for a pacemaker.

About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

About AVIM Therapy

AVIM therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will further evaluate the safety and efficacy of AVIM therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker.

About the FDA Breakthrough Device Program

The FDA Breakthrough Device Program, established in 2015, is designed to expedite the development, review, and potential market access of medical devices that may offer more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. The designation provides manufacturers with prioritized FDA review and early, frequent interactions with agency experts to efficiently address development and regulatory considerations. Breakthrough status may also support streamlined reimbursement pathways, including eligibility for New Technology Add-on Payments (NTAP) and Transitional Pass-Through Payments (TPT), by helping to demonstrate substantial clinical improvement.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the potential efficacy, safety and commercial value of the Company’s commercial product candidates, including the ability of AVIM therapy to favorably influence ventricular function, implementation of the Company’s ongoing BACKBEAT global pivotal study, the potential benefits of BDD, including its ability to expedite FDA reviews and streamline reimbursement pathways, the ability of the Company’s partnerships to accelerate clinical development, the nature and speed of the FDA’s review and regulatory process with respect to AVIM therapy, the ability to secure Medicare incremental payment programs, and the Company’s late-stage development programs and strategic partnerships. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2024, which was filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in Part II of the Company’s subsequently filed quarterly reports on Form 10-Q.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact

Silas Newcomb
Orchestra BioMed
(908) 723-4489
[email protected]

Media Contact

Kelsey Kirk-Ellis
Orchestra BioMed
(484) 682-4892
[email protected]



Posted on

New Jersey Resources Highlights the Success of the Coastal Climate Initiative in Celebration of Earth Day

New Jersey Resources Highlights the Success of the Coastal Climate Initiative in Celebration of Earth Day

WALL, N.J.–(BUSINESS WIRE)–
Created to help raise awareness about important environmental issues affecting the world around us, Earth Day has grown into a call to action to promote conservation, advance environmental sustainability best practices and protect the planet. For 55 years it has been inspiring people to get involved and help make a difference in their local communities. New Jersey Resources (NYSE: NJR), the parent company of New Jersey Natural Gas (NJNG), has worked to answer this call through its Coastal Climate Initiative (CCI).

“New Jersey Resources has a long history of leadership on environmental stewardship and support for our local communities,” said Katie Feery, director of Sustainability at New Jersey Resources. “As a company with significant operations along New Jersey’s coast, we created the Coastal Climate Initiative to invest in projects that have meaningful impact in the local communities we serve – protecting our ecosystems and building resilience. To date, we have committed more than $1.2 million to advance one-time and multi-year projects that will have long-term benefits for our environment.”

Launched in 2021, CCI is an umbrella program for NJR’s commitment to environmental and natural resource stewardship efforts, including financial support for projects, employee volunteerism and other forms of direct engagement. In 2023, the company pledged up to $2 million over five years from its charitable foundations to support environmental stewardship initiatives throughout its service territory. Over the past two years, NJR has committed over 60% of that funding to support vital projects that improve coastal ecology, community resiliency and nature-based solutions that help protect against the effects of climate change.

These projects include:

  • The Monmouth Conservation Foundation’s (MCF) and its work to restore and protect the Scudder Preserve. This 90-acre natural habitat located in Middletown, New Jersey is home to century forest, grasslands, streams and riparian corridors, ponds and nature trails. NJR’s support will help MCF conduct a natural resource inventory and create a site restoration and management plan for the property, as well as launch an educational outreach program. These efforts support forest, biodiversity and ecosystem restoration and expand public access through trail and facility improvements allowing local communities to benefit from this open space.
  • Monmouth University’s Urban Coast Institute (UCI) and its support of the Clam Cove Living Shoreline Pilot Project in Long Beach Township. The project was identified as a priority by the National Fish and Wildlife Foundation. As one of several key stakeholders involved with the project, UCI is committed to helping stabilize a widening breach in the cove and reduce the loss of marshland. These efforts support increased resiliency to the local communities and help improve habitats for fish, birds and other species.
  • The Conserve Wildlife Foundation and its efforts to preserve rare and imperiled wildlife species that live, breed and migrate in New Jersey. NJR’s support will help Conserve Wildlife with a beach nesting bird survey focused on the American Oystercatcher – a species that serves as an indicator for healthy ecosystems and a bellwether for potential impacts of climate change. It also includes the development of a new educational curriculum focused on the Monmouth County watershed and at-risk wildlife in NJR’s service territory and the development of baseline mapping of habitats to inform potential future resilience opportunities.
  • New Jersey Audubon and its leadership on the stewardship and resilience of the 500-acre Hovnanian Sanctuary located in Berkley Township, New Jersey and within the Pinelands National Reserve. Work includes the restoration of over 100 acres of upland forest, which will help improve water quality and enhance climate resiliency, as well as reduce the risk of wildfire; enhancement of 15+ acres of Atlantic white cedar forest to help protect this critical natural resource and the ecological and resiliency benefits it provides; and the development of improved recreational opportunities, such as walking rails, public access points, mapping and signage.
  • Rutgers University School of Environmental and Biological Sciences and the launch of its inaugural Vibrant Communities Program’s sustainability and resiliency project in Manitou Park, located in South Toms River Borough. The project’s focus will be on the creation and implementation of a sustainable landscaping master plan, as well as ongoing stewardship and management plan to maintain and improve the facility for long-term benefit to the community.
  • The Natural Resources Education Foundation to support the expansion and preservation, education and research work for shoreline stabilization and restoration at The Lighthouse Center. The Lighthouse Center is a 200-acre property of diverse coastal habitat in Waretown, Ocean County.

To learn more about CCI and NJR’s sustainability efforts, visit: https://www.njrsustainability.com/.

About New Jersey Resources:

New Jersey Resources (NYSE: NJR) is a Fortune 1000 company that, through its subsidiaries, provides safe and reliable natural gas and clean energy services, including transportation, distribution, asset management and home services. NJR is composed of five primary businesses:

  • New Jersey Natural Gas, NJR’s principal subsidiary, operates and maintains natural gas transportation and distribution infrastructure to serve customers in New Jersey’s Monmouth, Ocean, Morris, Middlesex, Sussex and Burlington counties.
  • Clean Energy Ventures invests in, owns and operates solar projects, providing customers with low-carbon solutions.
  • Energy Services manages a diversified portfolio of natural gas transportation and storage assets and provides physical natural gas services and customized energy solutions to its customers across North America.
  • Storage and Transportation serves customers from local distributors and producers to electric generators and wholesale marketers through its ownership of Leaf River and the Adelphia Gateway Pipeline, as well as our 50% equity ownership in the Steckman Ridge natural gas storage facility.
  • Home Services provides service contracts as well as heating, central air conditioning, water heaters, standby generators, solar and other indoor and outdoor comfort products to residential homes throughout New Jersey.

NJR and its over 1,300 employees are committed to helping customers save energy and money by promoting conservation and encouraging efficiency through Conserve to Preserve® and initiatives such as SAVEGREEN®.

For more information about NJR:

www.njresources.com.

Follow us on X.com (formerly Twitter) @NJNaturalGas.

“Like” us on facebook.com/NewJerseyNaturalGas.

Media Contact:

Mike Kinney

732-938-1031

[email protected]

Investor Contact:

Adam Prior

732-938-1145

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Environment Other Energy Utilities Oil/Gas Alternative Energy Sustainability Philanthropy Energy Other Philanthropy

MEDIA:

Logo
Logo
Posted on

One of U.S.’s Largest Drone Manufacturers of Small-Sized Drones Places its 6th Production Scale Order for Mobilicom’s Cybersecure Drone Solutions


D


emonstrat


es


continuous growth


through


ongoing


re-


orders


from


Tier-1 manufacturer


s


Customer


’s drones are gaining strong traction with U.S. Department of Defense (DoD) and other


d


efense purchasers

Palo Alto, California, April 22, 2025 (GLOBE NEWSWIRE) —  Mobilicom Limited (Nasdaq: MOB), a provider of cybersecurity and robust solutions for drones and robotics, today announced receipt of its latest, the sixth, commercial scale follow-on order for its SkyHopper PRO datalinks from one of the largest U.S. drone manufacturers of small-sized drones. The customer, a Tier-1 manufacturer with over $5 billion in annual sales, has integrated SkyHopper PRO as an essential component into drones sold to U.S. Department of Defense (DoD) programs.

“We believe that our field-proven, robust SkyHopper PRO datalinks is an ideal cybersecure system for the rapidly expanding small-sized drone market,” stated Mobilicom CEO and Founder Oren Elkayam. “Mobilicom’s systems’ performance, our recent addition to the U.S. Defense Innovation Unit’s Blue UAS Framework, our unparalleled service, and rapid delivery times are factors that are driving increasing demand for our solutions from the leading drone and robotics manufacturers in the world.”

Mobilicom’s SkyHopper PRO datalink was originally chosen by this customer, one of the largest drone manufacturers of small-sized drone in the U.S., over four other competing products following intensive field testing.

Mobilicom reported a 45% increase in year-over-year revenues in 2024, driven by a growing number of initial and repeat production scale orders from global Tier-1 customers.

SkyHopper PRO is a Secured Cognitive Software Defined Radio (SDR) with enhanced combat-proven performance, including in harsh environments. It offers what the Company believes to be the best performance-to-SWaP-C (Size, Weight, Power and Cost) in the market based on an internal study of competitor product offerings. The SkyHopper PRO complies with the U.S. National Defense Authorization Act (NDAA) and is certified by the U.S. Defense Innovation Unit’s Blue UAS Framework which provides a short list of approved vendors with advanced capabilities to UAS developers.

About Mobilicom

Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom’s large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world’s largest drone manufacturers, Mobilicom’s end-to-end solutions are used in mission-critical functions.

For investors, please use https://ir.mobilicom.com/
For company, please use www.mobilicom.com

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. For example, the Company is using forward-looking statements when it discusses the rapidly expanding small-sized drone market. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Mobilicom Limited’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission.

Forward-looking statements contained in this announcement are made as of this date, and Mobilicom Limited undertakes no duty to update such information except as required under applicable law.

For more information on Mobilicom, please contact:

Liad Gelfer

Mobilicom Ltd
[email protected]



Posted on

Mueller Industries, Inc. Reports First Quarter 2025 Earnings

Mueller Industries, Inc. Reports First Quarter 2025 Earnings

COLLIERVILLE, Tenn.–(BUSINESS WIRE)–
Mueller Industries, Inc. (NYSE: MLI) announces results for the first quarter of 2025. Comparisons are to the first quarter of 2024.

  • Net Income of $157.4 million versus $138.4 million
  • Operating Income of $206.3 million versus $183.4 million
  • Net Sales of $1.0 billion versus $849.7 million
  • Diluted EPS of $1.39 versus $1.21

First Quarter Financial and Operating Highlights:

  • COMEX copper averaged $4.57 per pound during the quarter, 18.4% higher than the average price of $3.86 per pound during the first quarter of 2024.
  • The increase in net sales was attributable to the inclusion of sales from two recently acquired businesses, and to higher selling prices related to the rise in raw material costs and tariffs. Modestly lower shipments in our Piping Systems segment, which largely stemmed from production challenges early in the quarter, combined with softer demand in some of our Industrial Metals businesses, partially offset the overall increase in net sales.
  • The results included a $14.5 million gain on the sale of an idle property, as well as a $5.0 million unrealized loss on short-term investments.
  • Net cash generated from operations was $113.6 million. We utilized $243.6 million during the period to repurchase just over 3 million shares of our common stock.
  • Our cash balance was $830.1 million at quarter end, and our current ratio remains strong at 4.3 to 1.

Regarding the quarter performance, Greg Christopher, Mueller’s CEO said, “We delivered very good results in the first quarter despite certain manufacturing disruptions, which have since been resolved, and the general economic landscape. We were particularly pleased with the positive contributions that our Nehring Electrical Works and Elkhart Products acquisitions made to our business, and we look forward to their continued improvement.”

Regarding the outlook, Mr. Christopher continued, “While markets and demand are in line with our year end comments and outlook, the tariff and trade policies have presented new challenges. Although we largely manufacture our products in the countries where they are consumed, we are not immune to the effects of tariffs. Where required, our teams are proactively and diligently taking appropriate price actions, and will continue to do so as necessary. As we have consistently demonstrated resilience during past periods of disruption, we are confident in our ability to effectively navigate the current environment.”

Mueller Industries, Inc. (NYSE: MLI) is an industrial corporation whose holdings manufacture vital goods for important markets such as air, water, oil and gas distribution; climate comfort; food preservation; energy transmission; medical; aerospace; and automotive. It includes a network of companies and brands throughout North America, Europe, Asia, and the Middle East.

*********************

Statements in this release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties. These include economic and currency conditions, continued availability of raw materials and energy, market demand, pricing, competitive and technological factors, and the availability of financing, among others, as set forth in the Company’s SEC filings. The words “outlook,” “estimate,” “project,” “intend,” “expect,” “believe,” “target,” “encourage,” “anticipate,” “appear,” and similar expressions are intended to identify forward-looking statements. The reader should not place undue reliance on forward-looking statements, which speak only as of the date of this report. The Company has no obligation to publicly update or revise any forward-looking statements to reflect events after the date of this report.

 

MUELLER INDUSTRIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)
 

 

 

For the Quarter Ended

(In thousands, except per share data)

 

March 29,

2025

 

March 30,

2024

 

 

 

 

 

Net sales

 

$

1,000,165

 

 

$

849,654

 

 

 

 

 

 

Cost of goods sold

 

 

728,185

 

 

 

608,703

 

Depreciation and amortization

 

 

17,123

 

 

 

9,169

 

Selling, general, and administrative expense

 

 

63,060

 

 

 

48,357

 

Gain on sale of assets

 

 

(14,465

)

 

 

—

 

 

 

 

 

 

Operating income

 

 

206,262

 

 

 

183,425

 

 

 

 

 

 

Interest expense

 

 

(25

)

 

 

(115

)

Interest income

 

 

9,901

 

 

 

17,245

 

Realized and unrealized (losses) gains on short-term investments

 

 

(5,010

)

 

 

365

 

Other income, net

 

 

92

 

 

 

630

 

 

 

 

 

 

Income before income taxes

 

 

211,220

 

 

 

201,550

 

 

 

 

 

 

Income tax expense

 

 

(51,475

)

 

 

(51,834

)

Loss from unconsolidated affiliates, net of foreign tax

 

 

(458

)

 

 

(8,007

)

 

 

 

 

 

Consolidated net income

 

 

159,287

 

 

 

141,709

 

 

 

 

 

 

Net income attributable to noncontrolling interests

 

 

(1,855

)

 

 

(3,346

)

 

 

 

 

 

Net income attributable to Mueller Industries, Inc.

 

$

157,432

 

 

$

138,363

 

 

 

 

 

 

Weighted average shares for basic earnings per share

 

 

110,739

 

 

 

111,416

 

Effect of dilutive stock-based awards

 

 

2,333

 

 

 

2,729

 

 

 

 

 

 

Adjusted weighted average shares for diluted earnings per share

 

 

113,072

 

 

 

114,145

 

 

 

 

 

 

Basic earnings per share

 

$

1.42

 

 

$

1.24

 

 

 

 

 

 

Diluted earnings per share

 

$

1.39

 

 

$

1.21

 

 

 

 

 

 

Dividends per share

 

$

0.25

 

 

$

0.20

 

 

 

 

 

 

 

 

 

 

 

MUELLER INDUSTRIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME, CONTINUED

(Unaudited)

 

 

 

 

 

 

 

For the Quarter Ended

(In thousands)

 

March 29, 2025

 

March 30, 2024

 

 

 

 

 

Summary Segment Data:

 

 

 

 

 

 

 

 

 

Net sales:

 

 

 

 

Piping Systems Segment

 

$

639,683

 

 

$

590,168

 

Industrial Metals Segment

 

 

251,913

 

 

 

156,067

 

Climate Segment

 

 

123,107

 

 

 

116,810

 

Elimination of intersegment sales

 

 

(14,538

)

 

 

(13,391

)

 

 

 

 

 

Net sales

 

$

1,000,165

 

 

$

849,654

 

 

 

 

 

 

Operating income:

 

 

 

 

Piping Systems Segment

 

$

158,164

 

 

$

142,680

 

Industrial Metals Segment

 

 

30,084

 

 

 

24,271

 

Climate Segment

 

 

35,624

 

 

 

32,575

 

Unallocated income (expenses)

 

 

(17,610

)

 

 

(16,101

)

 

 

 

 

 

Operating income

 

$

206,262

 

 

$

183,425

 

MUELLER INDUSTRIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

(Unaudited)

 

 

(In thousands)

 

March 29,

2025

 

December 28,

2024

ASSETS

 

 

 

 

Cash and cash equivalents

 

$

830,100

 

$

1,037,229

Short-term investments

 

 

43,497

 

 

21,874

Accounts receivable, net

 

 

553,106

 

 

450,113

Inventories

 

 

482,155

 

 

462,279

Other current assets

 

 

51,202

 

 

40,734

 

 

 

 

 

Total current assets

 

 

1,960,060

 

 

2,012,229

 

 

 

 

 

Property, plant, and equipment, net

 

 

515,208

 

 

515,131

Operating lease right-of-use assets

 

 

32,677

 

 

32,702

Other assets

 

 

723,359

 

 

730,844

 

 

 

 

 

Total assets

 

$

3,231,304

 

$

3,290,906

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current portion of debt

 

$

128

 

$

1,094

Accounts payable

 

 

223,609

 

 

173,743

Current portion of operating lease liabilities

 

 

8,358

 

 

8,117

Other current liabilities

 

 

224,276

 

 

215,033

 

 

 

 

 

Total current liabilities

 

 

456,371

 

 

397,987

 

 

 

 

 

Pension and postretirement liabilities

 

 

8,425

 

 

11,199

Environmental reserves

 

 

15,374

 

 

15,423

Deferred income taxes

 

 

27,736

 

 

25,742

Noncurrent operating lease liabilities

 

 

24,430

 

 

24,547

Other noncurrent liabilities

 

 

11,869

 

 

11,600

 

 

 

 

 

Total liabilities

 

 

544,205

 

 

486,498

 

 

 

 

 

Total Mueller Industries, Inc. stockholders’ equity

 

 

2,666,437

 

 

2,773,165

Noncontrolling interests

 

 

20,662

 

 

31,243

 

 

 

 

 

Total equity

 

 

2,687,099

 

 

2,804,408

 

 

 

 

 

Total liabilities and equity

 

$

3,231,304

 

$

3,290,906

MUELLER INDUSTRIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

For the Quarter Ended

(In thousands)

 

March 29,

2025

 

March 30,

2024

 

 

 

 

 

Cash flows from operating activities

 

 

 

 

Consolidated net income

 

$

159,287

 

 

$

141,709

 

Reconciliation of consolidated net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

17,123

 

 

 

9,250

 

Stock-based compensation expense

 

 

6,150

 

 

 

6,231

 

Provision for doubtful accounts receivable

 

 

99

 

 

 

1

 

Loss from unconsolidated affiliates

 

 

458

 

 

 

8,007

 

Dividends from unconsolidated affiliates

 

 

2,812

 

 

 

2,024

 

Insurance proceeds – noncapital related

 

 

—

 

 

 

15,000

 

Gain on disposals of properties

 

 

(14,465

)

 

 

(1,567

)

Unrealized loss on short-term investments

 

 

5,010

 

 

 

—

 

Gain on sales of securities

 

 

—

 

 

 

(365

)

Deferred income tax expense

 

 

1,651

 

 

 

940

 

Changes in assets and liabilities:

 

 

 

 

Receivables

 

 

(101,524

)

 

 

(75,200

)

Inventories

 

 

(18,542

)

 

 

22,502

 

Other assets

 

 

410

 

 

 

11,984

 

Current liabilities

 

 

57,702

 

 

 

33,948

 

Other liabilities

 

 

(2,598

)

 

 

(907

)

Other, net

 

 

(14

)

 

 

68

 

 

 

 

 

 

Net cash provided by operating activities

 

$

113,559

 

 

$

173,625

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

Capital expenditures

 

$

(16,592

)

 

$

(16,406

)

Purchase of short-term investments

 

 

(26,633

)

 

 

—

 

Purchase of long-term investments

 

 

(552

)

 

 

—

 

Proceeds from the sale of securities

 

 

—

 

 

 

96,465

 

Issuance of notes receivable with unconsolidated affiliates

 

 

—

 

 

 

(12,500

)

Proceeds from sales of properties

 

 

19,737

 

 

 

2,878

 

Investment received from noncontrolling interests

 

 

600

 

 

 

—

 

 

 

 

 

 

Net cash (used in) provided by investing activities

 

$

(23,440

)

 

$

70,437

 

 

 

 

 

 

 

 

 

 

 

MUELLER INDUSTRIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

 

 

 

 

For the Quarter Ended

(In thousands)

 

March 29,

2025

 

March 30,

2024

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

Dividends paid to stockholders of Mueller Industries, Inc.

 

$

(27,262

)

 

$

(22,255

)

Repurchase of common stock

 

 

(243,615

)

 

 

(27,930

)

Repayments of debt

 

 

(56

)

 

 

(56

)

Repayment of debt by consolidated joint ventures, net

 

 

—

 

 

 

(77

)

Net cash used to settle stock-based awards

 

 

(4,494

)

 

 

(2,489

)

Dividends paid to noncontrolling interests

 

 

(12,240

)

 

 

—

 

 

 

 

 

 

Net cash used in financing activities

 

$

(287,667

)

 

$

(52,807

)

 

 

 

 

 

Effect of exchange rate changes on cash

 

 

392

 

 

 

(670

)

 

 

 

 

 

(Decrease) increase in cash, cash equivalents, and restricted cash

 

 

(197,156

)

 

 

190,585

 

Cash, cash equivalents, and restricted cash at the beginning of the period

 

 

1,038,895

 

 

 

1,174,223

 

 

 

 

 

 

Cash, cash equivalents, and restricted cash at the end of the period

 

$

841,739

 

 

$

1,364,808

 

 

Jeffrey A. Martin

(901) 753-3226

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: Engineering Automotive Manufacturing HVAC Aerospace Manufacturing Other Manufacturing

MEDIA:

Logo
Logo
Posted on

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25

Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025

Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively

WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic dermatitis (AD). The Company expects to report data from the BroADen trial in the fourth quarter of 2025. Additionally, the Company has completed SAD/MAD dosing and follow-up in the KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025.

“The advancement of KT-621 in patients with AD is an important step in the development of this exciting program and underscores the potential of our unique technology to revolutionize the treatment of complex immuno-inflammatory diseases through oral medicines with biologics-like profiles,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an effective and convenient oral medicine, and we look forward to advancing the clinical program and sharing updates throughout the year.”

The BroADen single-arm, open label Phase 1b trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in approximately 20 adult patients with moderate to severe AD. Patients will be administered KT-621 once daily for 28 days. The key study objective is to show that robust STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing multiple Th2 biomarkers in the blood and on the transcriptome of active AD skin lesions. The study will also assess effects on clinical endpoints such as Eczema Area and Severity Index (EASI) and pruritus numerical rating scale (NRS).

Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.

About KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to provide the convenience of an oral medicine with the potential for biologics-like activity and in doing so reach broader patient populations compared to injectable biologics or other standards of care. In preclinical studies, KT-621 demonstrated dupilumab-like activity in several in vitro and in vivo models and was safe and well tolerated. KT-621, the first STAT6 directed medicine to enter clinical evaluation, has the opportunity to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Th2 diseases such as AD, asthma, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among others.

More information on the KT-621 BroADen trial in AD will be available on www.clinicaltrials.gov.

About Atopic Dermatitis

Atopic dermatitis (AD) is the most common form of eczema, a chronic inflammatory disease that causes the skin to become inflamed and irritated, making it extremely pruritic (itchy). AD occurs most frequently in children but also affects adults. It can affect a patient’s quality of life and lead to additional complications, such as infections and sleep loss. While there are currently available medicines for AD, such as topical therapies and injectable biologics, there remains a significant unmet need and opportunity to improve treatment options for millions of patients.

About Kymera Therapeutics

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Availability of Other Information About Kymera Therapeutics

For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and the progress, timing and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, the advancement of KT-621 in Phase 1 clinical testing, the expectation that two parallel Phase 2b clinical trials are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively and the intention to accelerate KT-621 development for subsequent parallel Phase 3 registration studies. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target,” “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future trials and the results of such trials, whether preclinical results will be indicative of the results of clinical trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements and other factors. These risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contact: 

Justine Koenigsberg
Vice President, Investor Relations
[email protected]
[email protected]
857-285-5300 



Posted on

LCI Industries First Quarter 2025 Conference Call Scheduled for May 6, 2025, at 8:30 a.m. ET

LCI Industries First Quarter 2025 Conference Call Scheduled for May 6, 2025, at 8:30 a.m. ET

ELKHART, Ind.–(BUSINESS WIRE)–
LCI Industries (NYSE: LCII), a leading supplier of engineered components to the recreation and transportation markets, will release its first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025.

Conference Call & Webcast

LCI Industries will also host a conference call to discuss its first quarter 2025 results on Tuesday, May 6, 2025, at 8:30 a.m. ET. The call will conclude with a question-and-answer session with questions from institutional investors and analysts.

The conference call can be accessed by dialing (833) 470-1428 for participants in the U.S. and (929) 526-1599 for participants outside the U.S. using the required access code 255011. Due to the high volume of companies reporting earnings at this time, please be prepared for hold times of up to 15 minutes when dialing in to the call. In addition, an online, real-time webcast, as well as a supplemental earnings presentation, will be available on the Company’s website, www.investors.lci1.com.

A replay of the conference call will be available for two weeks by dialing (866) 813-9403 for participants in the U.S. and (44) 204-525-0658 for those outside the U.S. and referencing access code 323974. A replay of the webcast will be available on the Company’s website immediately following the conclusion of the call.

About LCI Industries

LCI Industries (NYSE: LCII), through its Lippert subsidiary, is a global leader in supplying engineered components to the outdoor recreation and transportation markets. We believe our innovative culture, advanced manufacturing capabilities, and dedication to enhancing the customer experience have established Lippert as a reliable partner for both OEM and aftermarket customers. For more information, visit www.lippert.com.

Lillian Etzkorn, CFO

Phone: (574) 336-7659

E Mail:[email protected]

KEYWORDS: United States North America Indiana

INDUSTRY KEYWORDS: Retail Automotive Manufacturing Manufacturing Transportation Travel Recreational Vehicles Trucking Sports General Automotive Transport Other Manufacturing Aftermarket Outdoors Specialty Automotive Engineering

MEDIA:

Posted on

USA Rare Earth and The StudBuddy® Sign Memorandum of Understanding for Delivery of U.S.-Made Neo Magnets

New Partnership Underscores the Companies’ Shared Commitment to Securing a Domestic Rare Earth Supply Chain and Supporting U.S. Manufacturing

STILLWATER, Okla., April 22, 2025 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), which is building out a domestic rare earth element magnet production supply chain that includes the mining and processing of heavy rare earths and other critical minerals, today announced it has signed a memorandum of understanding (MOU) with The StudBuddy®, maker of the world’s simplest magnetic stud finder tool.

The MOU reflects USAR’s mission to establish and secure a domestic rare earth magnet supply chain for critical U.S. industries and everyday consumer products. This partnership, which brings together two organizations committed to domestic development and production, represents a significant milestone in the Company’s journey to bring the rare earth magnet industry to the U.S. following the March 31 commissioning of its Innovations Lab in Stillwater, Oklahoma.

Discussions will now progress toward a detailed multi-year supply agreement in which USAR will deliver approximately 20 metric tons of finished sintered neodymium magnets to StudBuddy annually.

“USA Rare Earth intends to bring high-powered magnet production back the to the U.S., and we are thrilled that our first customer announcement is with a quintessential American success story like The StudBuddy,” said Joshua Ballard, CEO of USA Rare Earth. “Weston Bernsen and his team, who share our commitment to U.S. manufacturing, are exactly the kind of customer we’re proud to partner with. I’m excited for what lies ahead.”

The StudBuddy was invented by Collin Bernsen, a framer, carpenter, builder, designer and general contractor seeking a simpler and more accurate way of locating framing studs behind drywall. Collin discovered the ease of locating nails and screws behind drywall using neodymium magnets, and therefore, stud location. This led to the patent and design of a simple device that would locate studs and hang on the wall for visual reference, which ultimately created The StudBuddy.

“We at The StudBuddy have been committed to supporting domestic manufacturing and suppliers from the very beginning,” said Weston Bernsen, Vice-President at The StudBuddy. “We have done all we can, despite increased costs and supply challenges, to source components from and produce our products in the United States. Continuing our pursuit of a fully domestic supply chain, we are proud to announce our partnership with USA Rare Earth, which will soon supply the high-powered permanent rare earth magnets we use in every one of our products. Over the coming years, not only will these magnets be made in the USA, but the raw material mining and oxide production will be fully vertically integrated domestically under the USA Rare Earth umbrella. What was once a dream is quickly becoming a reality, and we are very optimistic for what the future holds.”

For more information, please visit USARE.com and connect with us on LinkedIn and X.

About USA Rare Earth

USA Rare Earth is building a vertically integrated, domestic rare earth magnet production supply chain. USAR is currently constructing a 310k square foot rare earth sintered neo magnet manufacturing facility in Stillwater, Oklahoma. USAR also controls mining rights to the Round Top Mountain rare earth and critical minerals deposit in West Texas, which holds significant deposits of heavy rare earths, such as dysprosium and terbium, as well as gallium, beryllium, lithium and other critical tech minerals. USAR’s permanent neo magnets and rare earth minerals are required for a wide variety of products used in the defense, automotive, aviation, industrial, medical, and consumer electronics industries.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of USA Rare Earth’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this presentation, except as required by law.

Investor Relations Contact:

Lionel McBee
VP, Investor Relations
[email protected]

Media Relations Contact:

Cricket PR
Brian Hyland
(201) 410-4563
[email protected]